New polyol ether compounds and a process for their preparation. The process comprises reacting a polyol, a carbonyl compound, and hydrogen in the presence of hydrogenation catalyst, to provide the polyol ether. The molar ratio of polyol to carbonyl compound in the process is greater than 5:1.
A method for producing a diacylglycerol-rich fat or oil is provided. This method includes the steps of reacting an acyl group donor with an acyl group receptor, and separating unreacted material and byproducts by distillation for use as a part of the starting material in the subsequent cycle of production. The distillation is conducted such that the content of monoacylglycerol in the fat or oil after the distillation is 0.5 to 15% by weight.
[EN] PKC INHIBITORS FOR THE TREATMENT OF SEPTIC CHOLESTASIS WITH POLYMETHINE DYE TARGETING<br/>[FR] INHIBITEURS DE PKC POUR LE TRAITEMENT DE LA CHOLESTASE SEPTIQUE AVEC CIBLAGE À L'AIDE D'UN COLORANT DE TYPE POLYMÉTHINE
申请人:SMARTDYELIVERY GMBH
公开号:WO2020043667A1
公开(公告)日:2020-03-05
The invention relates to inhibitors of the PKC signaling pathway for use in the treatment of septic cholestasis, wherein the inhibitors are targeted into the liver by a selective nanostructured delivery system, wherein the selective nanostructured delivery system comprises at least one polymethine dye and at least one polymer and/or at least one lipid and/or at least one virus-like particle, wherein the at least one polymethine dye is a symmetrical or asymmetrical polymethine.
[EN] PKC INHIBITORS FOR THE TREATMENT OF SEPTIC CHOLESTASIS WITH CTM TARGETING<br/>[FR] INHIBITEURS DE PKC POUR LE TRAITEMENT DE LA CHOLESTASE SEPTIQUE AVEC CIBLAGE CTM
申请人:SMARTDYELIVERY GMBH
公开号:WO2020043668A1
公开(公告)日:2020-03-05
The invention relates to inhibitors of the PKC signaling pathway for use in the treatment of septic cholestasis, wherein the inhibitors are targeted into the liver by a selective nanostructured delivery system, wherein the selective nanostructured delivery system comprises at least one carbohydrate targeting moiety and at least one polymer and/or at least one lipid and/or at least one virus-like particle.
[EN] IODINATED PRODUCTS INTENDED FOR A USE FOR THE MEDICAL IMAGING AND THEIR METHODS OF PREPARATION<br/>[FR] PRODUITS IODÉS DESTINÉS À ÊTRE UTILISÉS POUR L'IMAGERIE MÉDICALE ET LEURS PROCÉDÉS DE PRÉPARATION
申请人:UNIV STRASBOURG
公开号:WO2013121284A1
公开(公告)日:2013-08-22
The present invention concerns an iodinated lipophilic compound of formula (I) or (II) : AG-R (I) or AG-X-R (II) wherein - AG represents an unsaturated or saturated (C8-C52) aliphatic hydrocarbon chain found in fatty acids having or not a double bond, an unsaturated or saturated aromatic cycle with an hydrocarbon chain, a sterol, an unsaturated or saturated (C8-C52) aliphatic hydrocarbon chain ended by an amino group having or not a double bound, - X represents a spacer such as a diacid, a diol (like aliphatic diol, polyethylene glycol comprising 1 to 50 ethylene glycol groups) or an amino acid, - R represents a benzene ring with one, two or three iodine atoms and a carboxylic group or an alcohol group.